

RECOMBINANT VON WILLEBRAND FACTOR COMPARISON CHART

Product	Cell line, molecule	Half-life	Viral inactivation	Vial size	Reconstitution device	Storage	Availability
<p>Vonvendi (vonicoα) Manufactured by Shire/Takeda</p>	Expressed in a Chinese hamster ovary (CHO) cell line.	Mean half-life of 18-22 hours	Polysorbate 80 (Tween-80)	650 IUs (in 5 mL of sterile water) 1,300 IUs (in 10 mL of sterile water) of VWF:RCo	Mix2Vial	Store below 30°C	<p>Vonvendi was approved by Health Canada in January 2019. It is indicated for the treatment and control of bleeding episodes in adults (age ≥ 18) diagnosed with von Willebrand disease (VWD) and for the perioperative management of bleeding in adults (age ≥ 18) diagnosed with VWD. No pediatric data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.</p> <p>Vonvendi is currently being evaluated by the Canadian Agency for Drugs and Technologies in Health (CADTH) but is not yet distributed by either Canadian Blood Services or Héma-Québec.</p>

Comments

Product monograph: www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffiles/product%20information/vonvendi-pm-en.pdf

Last revised – September 2, 2020